Phenformin Induces Caspase-dependent Apoptosis of FaDu Head and Neck Squamous Cell Carcinoma Cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Head and neck squamous cell carcinoma (HNSCC) is a significant global health concern.
• Current treatments for HNSCC have limitations, necessitating novel therapeutic strategies.
• Phenformin, an antidiabetic agent, has shown potential anticancer properties.

Purpose of the Study:

• To investigate the apoptotic effects of phenformin on HNSCC cells.
• To elucidate the molecular mechanisms underlying phenformin-induced apoptosis in HNSCC.
• To evaluate phenformin as a potential therapeutic agent for HNSCC.

Main Methods:

• Cytotoxicity was assessed using MTT and live/dead cell assays.
• Apoptosis and signaling pathways were analyzed via H&E staining, DAPI staining, caspase-3 activity assays, FACS, and western blotting.
• Specific molecular targets including caspases, PARP, MAPK, NF-κB, and AKT were examined.

Main Results:

• Phenformin induced significant apoptosis in FaDu HNSCC cells, characterized by morphological changes and nuclear condensation.
• Phenformin treatment activated the caspase cascade, leading to increased caspase-3 activity and cleavage of key apoptotic proteins (caspase-8, -9, -3, PARP).
• Phenformin downregulated phosphorylation of key signaling molecules, including MAPK, NF-κB, and AKT, in FaDu cells.

Conclusions:

• Phenformin triggers apoptosis in HNSCC cells through both extrinsic and intrinsic caspase-dependent pathways.
• The findings suggest that phenformin is a promising novel therapeutic agent for HNSCC.
• Further research into phenformin's efficacy and safety in HNSCC treatment is warranted.